Metabolic diseases
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
488
NCT04702490
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 15, 2020
Completion: Jun 30, 2022
NCT04773964
Study to Evaluate MET642 in Patients With NASH
Start: Mar 3, 2021
Completion: Dec 31, 2022
NCT05547906
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
Phase: Phase 1
Start: Nov 8, 2021
Completion: Feb 29, 2024
NCT07168226
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
Start: Sep 30, 2025
Completion: Jul 31, 2027
Loading map...